Trial & Approval Watch
Pivotal trial readouts, regulatory decisions and specialty pipeline activity. Entries are illustrative for clinical design purposes.
Trial & Approval Watch
Active Pipeline
| Trial / Agent | Phase / Status | Readout |
|---|---|---|
| SELECT-CV | Phase 3 | ▲ MACE −20% |
| FDA · lecanemab | Approved | ▲ Alzheimer's |
| CLEAR-Outcomes | Phase 3 | ▲ MACE −13% |
| EMPA-KIDNEY | Published | ▲ eGFR ↑ |
| DapaTAVI | Phase 4 | ▲ HF −28% |
| SUNRISE-1 | Phase 2 | ▼ Endpoint miss |
| FDA · donanemab | Approved | ▲ Early AD |
| NORSE-8 | Phase 3 | ▼ Halted (safety) |
| ORION-4 | Enrolling | ▲ LDL trial |
| FDA · resmetirom | Approved | ▲ MASH |
| ADAURA | Updated | ▲ OS benefit |
| RECOVERY | Rolling | ▲ Sepsis arm |
| CHAPTER-HF | Phase 3 | ▼ No benefit |
Specialty Pipeline
Momentum
| Specialty | Active Momentum |
|---|---|
| Cardiology | +1.24% |
| Oncology | +0.98% |
| Neurology | -0.72% |
| Infectious Dis. | +0.41% |
| Endocrinology | +0.55% |
| Nephrology | -0.19% |
| Pulmonology | +0.63% |
| Psychiatry | -0.08% |
| Pediatrics | +0.87% |
| Rheumatology | +1.02% |
| Gastroenterology | +0.34% |